Antibody drugs and cell therapies are at the heart of new biotechnology science. Not only do they show great promise when it comes to curing disease and helping patients, but also in creating value and growth. Biotech companies need to protect their scientific results and the corresponding investments with strong and durable patents. This is a complex task, with constantly evolving case law and practice on both sides of the Atlantic. In this webinar, AWA’s experts focus on how to create, defend and litigate these patents in Europe and elsewhere.
Patenting Antibody and Cell Therapies – What to Do and What Not to Do
You may also be interested in:
CNIPA issues draft regulations on GIs – what you need to know
On 18 September 2023 the China National Intellectual Property Administration (CNIPA) issued the “Draft Regulations on the Protection of
Reducing the burden – China issues rules on suspending trademark review cases
On June 13, 2023, the China National Intellectual Property Administration (CNIPA) issued an Interpretation on the Rules for Suspension
Patents and Intellectual Property – Strategic Aspects
As part of Redeye’s ProView series, Jessica Martinsson, COO of Sprint Bioscience joins European patent attorneys Joanna Applequist and